About the Event
InSitu Biologics has developed a precision local delivery and proprietary controlled-release technology that increases the safety and efficacy of multiple treatments.
The first target of this technology is post-operative pain management due to the enormous size of the market and the huge benefit it will provide to society.
- Post operative pain is a leading reasons physicians prescribe opioids
- One injection provides 5 days of pain management without OPIOIDS!
- Most patients can transition directly to ibuprofen or other OTC pain medication
- InSitu has more than 20 patents on its product and process
Join our webinar with InSitu Biologics CEO, Kevin Bassett, to hear more about the company’s path to approval in pain management and future opportunities in cancer, anti-inflammatory, and antibiotic drug delivery.